Hidrasec (Racecadotril)

Hidrasec is primarily indicated for the symptomatic treatment of acute, non‑invasive diarrhea in children and adults, helping to reduce stool frequency and volume without affecting intestinal motility.

• Management of acute watery diarrhea in pediatric patients.
• Adjunct therapy for adult patients with acute infectious diarrhea.
• Supportive care to limit fluid loss during short‑term diarrheal episodes.
• Use in clinical settings where opioid‑based antidiarrheals are contraindicated.
• Part of rehydration protocols combined with oral rehydration solutions.

• Racecadotril, the active component of Hidrasec, acts peripherally by inhibiting the enzyme enkephalinase (neutral endopeptidase). This inhibition prevents the breakdown of endogenous enkephalins in the intestinal mucosa, allowing them to bind opioid receptors on enteric neurons. The resulting activation reduces secretion of water and electrolytes into the intestinal lumen, thereby decreasing stool output while preserving normal gut motility.

Like many antidiarrheal agents, Hidrasec may be associated with adverse reactions that range from mild and transient to rare but serious. Reported events are based on clinical observations and post‑marketing data.

Common

• Nausea or mild stomach discomfort, usually transient and not requiring treatment.
• Headache, often mild and resolves without intervention.
• Dizziness, typically short‑lived and unrelated to severe neurologic events.
• Transient increase in abdominal pain or cramping, which usually subsides after continued therapy.

Serious

• Severe allergic reaction, presenting as rash, itching, swelling of the face or lips, or difficulty breathing, requiring immediate medical attention.
• Persistent constipation that may lead to bowel obstruction if not addressed.
• Elevation of liver enzymes observed in rare laboratory monitoring, indicating possible hepatic involvement.
• Acute pancreatitis, an extremely rare event characterized by severe abdominal pain and elevated pancreatic enzymes.

When prescribing or dispensing Hidrasec, clinicians should consider several precautionary measures to ensure safe use, especially in vulnerable populations or when co‑existing conditions exist.

• Assess hydration status before initiating therapy, as adequate fluid replacement remains essential.
• Use with caution in patients with known hypersensitivity to racecadotril or any excipients.
• Avoid in individuals with severe hepatic impairment until safety is established.
• Monitor for signs of constipation, particularly in children and the elderly.
• Consider alternative therapy for patients with a history of pancreatitis.
• Do not substitute for oral rehydration solutions; Hidrasec should complement, not replace, fluid therapy.

Hidrasec may interact with other medicines that affect intestinal secretion, renal function, or enzyme activity; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concomitant use with potent opioid agonists that act centrally, as they may mask symptoms of bowel obstruction.
• Combination with other enkephalinase inhibitors, which could lead to excessive enkephalin accumulation.

Use with caution

• Co‑administration with diuretics, because altered fluid balance may modify the clinical response.
• Concurrent use of hepatotoxic drugs, given the rare reports of liver enzyme elevation.
• Use alongside anticholinergic agents that reduce gastrointestinal motility, potentially increasing constipation risk.
• Administration with drugs that require acidic gastric pH for absorption, as racecadotril’s formulation may alter gastric environment.